Prof Michael Brown, Director of
Cancer Clinical Trials Unit, Senior Medical Oncologist at Royal Adelaide
Hospital Cancer Centre, Clinical Professor, School of Medicine, University of
Adelaide will talk about "GD2-specific CAR
T cell theapy for metastatic melanoma".
Tuesday 12 April, 2.30-3.30pm, Boardrooms A & B,
Level 3, Hudson Building
Light
refreshments to follow presentation outside the Boardrooms.
In a bench to bedside effort, researchers in
the Translational Oncology Laboratory are
applying advances in immunotherapeutic technologies to the treatment of
melanoma, myeloid leukemia,
brain and lung cancers, which affect
millions around the world. The two major technologies of interest are chimeric
antigen receptors (CARs) for re-directing lymphocytes toward cancers and
antibody drug conjugates (ADCs) for targeting potent cytotoxins to cancers.
We
are developing pre-clinical and clinical approaches for the treatment of these
cancers to aid in diagnosis, therapy monitoring and treatment. Much of our
research is collaborative, working in association with the RAH Cancer Clinical
Trials Unit and partnering with other laboratories within the Centre for Cancer
Biology.
No comments:
Post a Comment